Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083

Mitchell KM, Boily MC, Hanscom B, Moore M, Todd J, Paz-Bailey G, Wejnert C, Liu A, Donnell DJ, Grinsztejn B, Landovitz RJ, Dimitrov DT. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. Lancet Reg Health Am. 2023 Jan 17;18:100416. doi: 10.1016/j.lana.2022.100416. PMID: 36844011; PMCID: PMC9950652.


Related Posts